Clinical Trials
38 trialsNCT05374512 2026-05-15
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
AstraZeneca
Phase 3 Active not recruiting
NCT02609776 2026-05-08
CHRYSALIS
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04538664 2026-05-08
PAPILLON
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04988295 2026-05-08
MARIPOSA-2
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03456076 2026-05-05
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03043872 2026-04-22
CASPIAN
AstraZeneca
Phase 3 Active not recruiting
NCT03288545 2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2 Terminated
NCT03547973 2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2 Recruiting
NCT03164616 2026-03-13
POSEIDON
AstraZeneca
Phase 3 Active not recruiting
NCT05091567 2026-03-10
IMforte
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03036098 2026-03-06
CheckMate901
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03088540 2026-02-23
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals
Phase 3 Completed
NCT03635567 2026-02-04
KEYNOTE-826
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02998528 2026-01-06
CheckMate 816
Bristol-Myers Squibb
Phase 3 Completed
NCT04269200 2025-12-23
DUO-E
AstraZeneca
Phase 3 Active not recruiting
NCT03215706 2025-12-17
CheckMate 9LA
Bristol-Myers Squibb
Phase 3 Completed
NCT01358877 2025-11-28
APHINITY
Hoffmann-La Roche
Phase 3 Completed
NCT04472429 2025-11-03
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
Incyte Corporation
Phase 3 Completed
NCT02477826 2025-10-30
CheckMate 227
Bristol-Myers Squibb
Phase 3 Completed
NCT03036488 2025-10-29
MK-3475-522
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04025879 2025-10-16
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04035486 2025-10-10
FLAURA2
AstraZeneca
Phase 3 Active not recruiting
NCT05722015 2025-09-11
MK-3475A-D77
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03981796 2025-09-03
RUBY
Tesaro, Inc.
Phase 3 Active not recruiting
NCT02358031 2025-07-18
MK-3475-048
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04223856 2025-06-13
EV-302
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT03800134 2025-06-11
AEGEAN
AstraZeneca
Phase 3 Active not recruiting
NCT04974398 2025-04-13
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Akeso
Phase 3 Active not recruiting
NCT01828099 2025-01-16
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Novartis
Phase 3 Completed
NCT02819518 2024-11-27
KEYNOTE-355
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02775435 2024-10-08
KEYNOTE-407
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02578680 2024-09-20
MK-3475-189
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02899299 2024-05-21
CheckMate743
Bristol-Myers Squibb
Phase 3 Completed
NCT02684058 2023-12-13
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Novartis
Phase 2 Completed
NCT02220894 2023-10-10
Keynote 042
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02763579 2023-07-28
IMpower133
Hoffmann-La Roche
Phase 3 Completed
NCT02409342 2023-03-15
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
Hoffmann-La Roche
Phase 3 Completed
NCT02367781 2021-08-09
IMpower130
Hoffmann-La Roche
Phase 3 Completed